SEC Form 4 · accession 0001078782-18-000112
Zivo Bioscience, Inc. · ZIVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew A Dahl
Officer — President/CEO
Period of report
Nov 8, 2017
Accepted (ET)
Feb 9, 2018 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001101026
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Purchase WarrantF1 | $0.08 | Nov 8, 2017 | A | 10,000,000 | A | Nov 8, 2017 | Nov 8, 2022 | Common Stock | 10,000,000 | 10,000,000 | D |
Explanation of responses
- F1The warrants were issued to the reporting person as compensation for his services as President and CEO.